Volume: 45  Suppl: 4 - September 2017
Show Abstracts | << Back
EDITORIAL
1.Editorial
Murat Özdemir
PMID: 28947722  Page III
DOWNLOAD  (Article in Turkish)
INVITED REVIEW
2.EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism
Cihangir Kaymaz
PMID: 28947723  doi: 10.5543/tkda.2017.02646  Pages 1 - 7
Abstract | Full Text PDF  (Article in Turkish)
3.After the GEMINI-ACS-1 trial
Mehmet Birhan Yılmaz
PMID: 28947724  doi: 10.5543/tkda.2017.52358  Pages 8 - 9
Abstract | Full Text PDF  (Article in Turkish)
4.PIONEER AF-PCI trial
Murat Özdemir
PMID: 28947725  doi: 10.5543/tkda.2017.04524  Pages 10 - 14
Abstract | Full Text PDF  (Article in Turkish)
5.Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials
Rabia Akıllı, Mesut Demir
PMID: 28947726  doi: 10.5543/tkda.2017.27632  Pages 15 - 23
Abstract | Full Text PDF  (Article in Turkish)
6.Importance of adherence and persistence in anticoagulant treatment: Advantages of once daily dosing
Erdem Diker
PMID: 28947727  doi: 10.5543/tkda.2017.03446  Pages 24 - 25
Abstract | Full Text PDF  (Article in Turkish)
7.How should one read “real-life data” regarding NOAC’s? “The case with rivaroxaban”
Özgür Aslan
PMID: 28947728  doi: 10.5543/tkda.2017.33903  Pages 26 - 32
Abstract | Full Text PDF  (Article in Turkish)